HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $115 Price Target

Benzinga · 12/30/2025 15:40
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $115 price target.